

4.0.03 DOC Cmte minutes

Prostate Cancer Committee meeting

Date: 09/01/2018

Location: NICE – London

Minutes: Final



Committee members present:	
Waqar Shah (WS) (Chair)	Present for all
Abi Ademoyero (AA)	Present for all
Pauline Bagnall (PB)	Present for all
Guy Chetiyawardana (GC)	Present for all
Charles Frost (CF)	Present for all
John Graham (JG)	Present for all
Sadaf Haque (SH)	Present for all
Peter Jenkins (PJ)	Present for all
Howard Kynaston (HK)	Present for all
Sanjeev Madaan (SM)	Present for all
Brian McGlynn (BM)	Present until the partway through the drafting of recommendations under item 3
Jonathan Richenberg (JR)	Present for all
Mark Robinson (MR)	Present for all
Karen Stalbow (KS)	Present for all
Rhiannon Walters-Davies (RWD)	Present for all

In attendance:		
Jean Bennie (JB)	GUT – Technical Analyst	Present for all
Chris Carmona (CC)	GUT – Senior Technical Analyst	Present for all
Fadi Chehadah (FC)	NICE – Health Economist	Present for all
Rupert Franklin (RF)	NICE – Senior Guidelines Commissioning Manager	Present for all
Gareth Haman (GH)	NICE – Senior Medical Editor	Present for items 1 – 2
Jenny Kendrick (JK)	NICE – Information Specialist	Present for all
Adam O’Keefe (AO)	GUT – Project Manager	Present for all
Katrina Penman (KP)	NICE – Technical Adviser	Present for item 5
Gabriel Rogers (GR)	NICE – Technical Adviser (HE)	Present for all

4.0.03 DOC Cmte minutes

Apologies:	
Jon Oxley	Committee member
Sus Spiers	GUT - Associate Director

Observer:	
Alice Biggane (AB)	(Present for items 1 – 7)

1. Introductions and guideline committee working

The Chair welcomed the Committee members and attendees to the third meeting on Prostate cancer. The Chair introduced FD as the new Health Economist on the guideline and RWD as a recently appointed co-opted pharmacist. The Committee members and attendees introduced themselves. The Chair informed the Committee of apologies received, as listed above. The Chair explained that JO was absent from this meeting due to a conflict of interest relevant to the topics being discussed.

The Chair outlined the objectives of the meeting, which included:

- Presentation on the role of the editor and their interaction with the work of the committee
- Presentation of clinical and Health economic evidence supporting review questions 5 and 6
- A discussion on the ASCENDE RT study

Minutes of the previous meeting were agreed as an accurate record.

The Chair asked all attendees to verbally declare any interests. No new interests were declared. Having reviewed the registry of previous declarations, the Chair declared that all attendees could fully participate in the meeting.

2. Editorial presentation

The Chair introduced GH, who delivered a presentation which outlined the role of the Senior Medical Editor and how this interacts with the work of the committee. The Chair then invited the Committee to ask any questions before thanking GH for his presentation.

3. Review Question 5: What is the most clinically- and cost-effective scheduling of docetaxel added to standard treatment for the treatment of

4.0.03 DOC Cmte minutes

hormone-sensitive locally-advanced prostate cancer?

Review Question 6: What is the most clinically- and cost-effective scheduling of docetaxel added to standard treatment for the treatment of hormone-sensitive metastatic prostate cancer?

JB recapped the search protocols and presented the clinical evidence supporting Review Questions 5 and 6 for the committee's consideration. GR provided a brief recap of the principles of economic evaluation before presenting the health economic evidence identified for this question.

The committee discussed the evidence presented and drafted three recommendations. Recommendations were drafted after item 4.

4. Discussion on the ASCENDE RT trial

The committee discussed the ASCENDE RT trial and agreed that one of its arms constituted conventional treatment in the UK and therefore the trial should be included in the relevant evidence review. The committee agreed a deviation from the review protocol and asked for brachytherapy only studies to be included for completeness.

5. Next steps

The Chair confirmed the venue, date and time of the next meeting, as detailed below and thanked the Committee and others present for their contribution to the meeting before closing the meeting.

Date of next meeting: Tuesday 20 February 2018

Location of next meeting: NICE - Manchester